BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis

BCRX scores 78/100 on Financial Health, which measures profitability, business quality, balance sheet strength, and cash flow. Higher scores reflect stronger compounder characteristics.

Worth tracking, but timing is mixed — not a clear setup yet. Entry Status is a timing read — separate from business quality.

This opportunity was published on Aug 18, 2026 at an entry price of $9.94. Performance is tracked publicly from that baseline.

Return is measured from the published entry price to the latest quote, then compared with QQQ from the same date. Alpha is the difference between the two.

No. Compound Radar publishes research models and track records. Do your own research before making investment decisions.

Financial Health scores business quality from profitability, growth, balance sheet, and cash flow. Entry Status is a separate timing read from trend, momentum, valuation, support, and catalysts.

When a setup is published, the entry date and price become the public baseline. Performance is marked to market and compared with QQQ, including wins and losers.

QQQ is a liquid growth-oriented benchmark that fits the kinds of businesses Compound Radar tends to research better than a broad market average alone.